Rallybio Corporation
RLYB
$0.535
$0.0715.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -35.63% | -6.70% | 81.87% | 304.37% | -- |
| Gross Profit | 37.22% | 8.20% | -79.60% | -302.09% | -- |
| SG&A Expenses | -28.76% | -27.82% | -27.35% | -21.97% | -14.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.51% | -26.73% | -10.16% | -0.15% | 7.10% |
| Operating Income | 34.61% | 27.54% | 10.96% | 0.55% | -7.10% |
| Income Before Tax | 36.83% | 22.52% | 5.04% | -4.76% | -9.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.83% | 22.52% | 5.04% | -4.76% | -9.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.83% | 22.52% | 5.04% | -4.76% | -9.79% |
| EBIT | 34.61% | 27.54% | 10.96% | 0.55% | -7.10% |
| EBITDA | 34.65% | 27.57% | 10.96% | 0.53% | -7.14% |
| EPS Basic | 42.38% | 27.36% | 11.75% | 8.17% | 8.67% |
| Normalized Basic EPS | 39.77% | 31.74% | 16.23% | 12.32% | 12.60% |
| EPS Diluted | 42.38% | 27.36% | 11.75% | 8.17% | 8.67% |
| Normalized Diluted EPS | 39.77% | 31.74% | 16.23% | 12.32% | 12.60% |
| Average Basic Shares Outstanding | 9.76% | 7.65% | 8.60% | 13.05% | 18.36% |
| Average Diluted Shares Outstanding | 9.76% | 7.65% | 8.60% | 13.05% | 18.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |